Abstract:Cellular senescence is a stress-responsive cell-cycle arrest program that terminates the further expansion of (pre-)malignant cells. Key signalling components of the senescence machinery, such as p16INK4a, p21CIP1 and p53, as well as trimethylation of lysine 9 at histone H3 (H3K9me3), also operate as critical regulators of stem-cell functions (which are collectively termed 'stemness'). In cancer cells, a gain of stemness may have profound implications for tumour aggressiveness and clinical outcome. Here we investigated whether chemotherapy-induced senescence could change stem-cell-related properties of malignant cells. Gene expression and functional analyses comparing senescent and non-senescent B-cell lymphomas from Eμ-Myc transgenic mice revealed substantial upregulation of an adult tissue stem-cell signature, activated Wnt signalling, and distinct stem-cell markers in senescence. Using genetically switchable models of senescence targeting H3K9me3 or p53 to mimic spontaneous escape from the arrested condition, we found that cells released from senescence re-entered the cell cycle with strongly enhanced and Wnt-dependent clonogenic growth potential compared to virtually identical populations that had been equally exposed to chemotherapy but had never been senescent. In vivo, these previously senescent cells presented with a much higher tumour initiation potential. Notably, the temporary enforcement of senescence in p53-regulatable models of acute lymphoblastic leukaemia and acute myeloid leukaemia was found to reprogram non-stem bulk leukaemia cells into self-renewing, leukaemia-initiating stem cells. Our data, which are further supported by consistent results in human cancer cell lines and primary samples of human haematological malignancies, reveal that senescence-associated stemness is an unexpected, cell-autonomous feature that exerts its detrimental, highly aggressive growth potential upon escape from cell-cycle blockade, and is enriched in relapse tumours. These findings have profound implications for cancer therapy, and provide new mechanistic insights into the plasticity of cancer cells.

subset of chromosome ends , leading to propagation of a DNA damage response that induces senescence or cell death (

A DNA damage checkpoint response in telomere-initiated senescence

Senescence Reprogramming by MTHFD2 Deficiency Facilitates Tumor Progression

In my end is my beginning: control of end resection and DSBR pathway ‘choice’ by cyclin-dependent kinases

Cell death caused by single-stranded oligodeoxynucleotide-mediated targeted genomic sequence modification.

Spontaneous DNA damage to the nuclear genome promotes senescence, redox imbalance and aging

Distinct cellular responses to replication stress leading to apoptosis or senescence

Uncoupling of mTORC1 from E2F activity maintains DNA damage and senescence

Slowly Repaired Bulky DNA Damages Modulate Cellular Redox Environment Leading to Premature Senescence

Is Senescence Reversible?

DNA methylation protects cancer cells against senescence

A cmap-enabled gene expression signature-matching approach identifies small-molecule inducers of accelerated cell senescence

Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects

DNA damage, aging, and cancer.

Telomeric 8-oxo-guanine drives rapid premature senescence in the absence of telomere shortening

The DNA damage response at dysfunctional telomeres, and at interstitial and subtelomeric DNA double-strand breaks

Dynamic Transcriptome Profiling in DNA Damage-Induced Cellular Senescence and Transient Cell-Cycle Arrest

Senescence-associated reprogramming promotes cancer stemness

A Selective Requirement for 53BP1 in the Biological Response to Genomic Instability Induced by Brca1 Deficiency.

DNA damage and the balance between survival and death in cancer biology

Replication Stress Induces ATR/CHK1-Dependent Nonrandom Segregation of Damaged Chromosomes.